Similar articles for PMID: 31977495

Year	Number of Results
2003	2
2008	1
2009	1
2011	1
2012	1
2013	2
2014	4
2015	4
2016	15
2017	19
2018	22
2019	28
2020	58
2021	66
2022	49
2023	12
2024	1

1

Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.

Chen B, Bathala TK, Xu G, Teyateeti A, Chapin BF, Tang C, Tu SM, Macapinlac HA, Lu Y. Chen B, et al. Clin Nucl Med. 2020 May;45(5):349-355. doi: 10.1097/RLU.0000000000002963. Clin Nucl Med. 2020. PMID: 31977495

2

More advantages in detecting bone and soft tissue metastases from prostate cancer using ¹⁸F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Pianou NK, et al. Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003 Free article.

3

Prospective evaluation of fluciclovine (¹⁸F) PET-CT and MRI in detection of recurrent prostate cancer in non-prostatectomy patients.

Akin-Akintayo O, Tade F, Mittal P, Moreno C, Nieh PT, Rossi P, Patil D, Halkar R, Fei B, Master V, Jani AB, Kitajima H, Osunkoya AO, Ormenisan-Gherasim C, Goodman MM, Schuster DM. Akin-Akintayo O, et al. Eur J Radiol. 2018 May;102:1-8. doi: 10.1016/j.ejrad.2018.02.006. Epub 2018 Feb 24. Eur J Radiol. 2018. PMID: 29685521 Free PMC article.

4

Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for ¹⁸F-fluciclovine-PET/CT in delineating sites of recurrence and identifying patients with oligometastatic disease.

Kim EH, Siegel BA, Teoh EJ, Andriole GL; LOCATE Study Group. Kim EH, et al. Urol Oncol. 2021 Jun;39(6):365.e9-365.e16. doi: 10.1016/j.urolonc.2020.10.017. Epub 2020 Nov 5. Urol Oncol. 2021. PMID: 33160848 Free PMC article.

5

Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.

Odewole OA, Tade FI, Nieh PT, Savir-Baruch B, Jani AB, Master VA, Rossi PJ, Halkar RK, Osunkoya AO, Akin-Akintayo O, Zhang C, Chen Z, Goodman MM, Schuster DM. Odewole OA, et al. Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1773-83. doi: 10.1007/s00259-016-3383-8. Epub 2016 Apr 18. Eur J Nucl Med Mol Imaging. 2016. PMID: 27091135 Free PMC article.

6

The Clinical Utility of ¹⁸F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: an Academic Center Experience Post FDA Approval.

Nakamoto R, Harrison C, Song H, Guja KE, Hatami N, Nguyen J, Moradi F, Franc BL, Aparici CM, Davidzon G, Iagaru A. Nakamoto R, et al. Mol Imaging Biol. 2021 Aug;23(4):614-623. doi: 10.1007/s11307-021-01583-3. Epub 2021 Jan 19. Mol Imaging Biol. 2021. PMID: 33469884

7

¹⁸F-fluciclovine PET-CT and ⁶⁸Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.

Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J. Calais J, et al. Lancet Oncol. 2019 Sep;20(9):1286-1294. doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30. Lancet Oncol. 2019. PMID: 31375469 Free PMC article. Clinical Trial.

8

Diagnostic performance of 18F-fluciclovine PET/CT for regional lymph node metastases in patients with primary prostate cancer: a multicenter phase II clinical trial.

Suzuki H, Jinnouchi S, Kaji Y, Kishida T, Kinoshita H, Yamaguchi S, Tobe T, Okamura T, Kawakita M, Furukawa J, Otaka A, Kakehi Y. Suzuki H, et al. Jpn J Clin Oncol. 2019 Sep 1;49(9):803-811. doi: 10.1093/jjco/hyz072. Jpn J Clin Oncol. 2019. PMID: 31095314 Clinical Trial.

9

Utility of ¹⁸F-Fluciclovine PET/CT for Detecting Prostate Cancer Recurrence in Patients With Low (< 1 ng/mL) or Very Low (< 0.3 ng/mL) Prostate-Specific Antigen Levels.

Wang Y, Chow DZ, Ebert E, Tajmir S, Scott JA, Palmer EL. Wang Y, et al. AJR Am J Roentgenol. 2020 Oct;215(4):997-1001. doi: 10.2214/AJR.19.22180. Epub 2020 Jun 22. AJR Am J Roentgenol. 2020. PMID: 32569513

10

Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer.

Chen B, Wei P, Macapinlac HA, Lu Y. Chen B, et al. Nucl Med Commun. 2019 Sep;40(9):940-946. doi: 10.1097/MNM.0000000000001051. Nucl Med Commun. 2019. PMID: 31343613

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

237 results

Results by year